Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.
| Revenue (Most Recent Fiscal Year) | $183.52M |
| Net Income (Most Recent Fiscal Year) | $-13.25M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 88.53 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -57.81% |
| Return on Equity (Trailing 12 Months) | -59.44% |
| Return on Assets (Trailing 12 Months) | -21.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.78 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.72 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.61 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.44 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 85.98M |
| Free Float | 73.16M |
| Market Capitalization | $743.72M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 1.83 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.91% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |